menu
    • menu
    [{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Generate Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CAR T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis"}]

    Find Clinical Drug Pipeline Developments & Deals by Roswell Park Comprehensive Cancer Center

    Menu

    Roswell Park Comprehensive Cancer Center

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR T-Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Generate Biomedicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Acc...

                            Details : The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 01, 2023

                            Lead Product(s) : CAR T-Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Generate Biomedicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Amp...

                            Details : Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.

                            Product Name : Ampligen

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod,Celecoxib,Interferon Alfa-2B

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial...

                            Details : Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.

                            Product Name : Ampligen

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 30, 2022

                            Lead Product(s) : Rintatolimod,Celecoxib,Interferon Alfa-2B

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod,Celecoxib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 M...

                            Details : The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.

                            Product Name : Ampligen

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 11, 2022

                            Lead Product(s) : Rintatolimod,Celecoxib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2B

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen as a Component of a Chemokine M...

                            Details : Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.

                            Product Name : Ampligen

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 11, 2022

                            Lead Product(s) : Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2B

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            Roswell Park Comprehensive Cancer Center

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : $14.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M

                            Details : Prestigious grant will fund 5 clinical trials in patients with 3 cancer types.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            April 06, 2020

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : $14.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth